We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Orthofix (OFIX) Earnings Beat Estimates in Q4, Margins Fall
Read MoreHide Full Article
Orthofix (OFIX - Free Report) reported fourth-quarter 2018 adjusted earnings of $55 cents per share, up 5.8% year over year. The figure beat the Zacks Consensus Estimate by 17%. Adjusting for the operating loss incurred due to the acquisition of Spinal Kinetics, adjusted EPS in the quarter was 62 cents, reflecting 19.2% growth over the prior-year quarter.
Reported EPS in the quarter came in at 46 cents, showing a massive year-over-year surge of 475%.
For the full year, the company delivered an adjusted EPS of $1.79, marking an increase of 10.5% from a year ago. The bottom line beat the Zacks Consensus Estimate by 2.3%.
Revenues in the fourth quarter came in at $121.1 million, up 3.6% year over year. The figure, however, missed the Zacks Consensus Estimate by 0.6%. Excluding contributions from Spinal Kinetics, net sales increased 1.4% on a reported basis and 1.7% at constant exchange rate or CER.
For the full year, revenues totaled $453 million, up 4.4% from the year-ago period. The top line missed the Zacks Consensus Estimate by a meager 0.2%.
Segmental Analysis
The key operating segment of Orthofix is Orthofix Spine which comprises product lines like Bone Growth Therapies, Spinal Implants, Biologics, Orthofix Extremities. For the quarter under review, revenues from Bone Growth Therapies totaled $52.8 million, up 6.1 % year over year both on a reported basis and at CER.
Spinal implants posted revenues of $24.9 million, up 17.9% (18.5% at CER). This included $3.59 million from spinal kinetics. Biologics recorded revenues of $16 million, down 4.8%, both on a reported basis and at CER. Revenues from Orthofix Extremities grossed $27.2 million, down 6.4% on a reported basis and 3.6% at CER.
Margin details
In the fourth quarter of 2018, gross profit increased 2.3% year over year to $95.4 million. However, gross margin contracted 100 basis points (bps) to 78.8%. Adjusted operating profit declined 28% from the year-ago quarter to $12.8 million. The decline was led by a year-over-year increase in operating expenses. As a result, operating margin contracted 472 bps to 10.6%.
Operational update
Orthofix exited 2018 with a cash equivalent of $69.6 million compared with $81.2 million at the end of 2017. Net cash from operating activities at the end of 2018 was $49.9 million, reflecting an increase from $38.9 million in the year-ago period.
Guidance for 2019
Orthofix issued the 2019 financial guidance. Adjusted EPS at the end of 2019 is projected in the band of $1.75-$1.82 million. The Zacks Consensus Estimate of $1.86 is above the high end of the guidance. Revenues at the end of 2019 are projected in the range of $472-$477 million. The Zacks Consensus Estimate of $480.5 million is also above the high end of the guidance provided by the company.
Our take
Orthofix ended 2018 on a mixed note with earnings surpassing estimates but revenues missing the same by a narrow margin. Barring Extremities and Biologics, the other key operating segments saw year-over-year revenue growth. It is concerning to note that both gross and operating margin contracted in the fourth quarter. However, the recent FDA approval of the M6-C Artificial Cervical disc reflects the steady progress in the company’s spine business.
Zacks Rank & Other Key Picks
Orthofix sports a Zacks Rank #1 (Strong Buy). A few other top-ranked medical stocks are Abbott Laboratories (ABT - Free Report) , AngioDynamics Inc. (ANGO - Free Report) and CONMED, Corp. (CNMD - Free Report) .
Abbott reported fourth-quarter 2018 adjusted EPS of 81 cents, in line with the Zacks Consensus Estimate. Revenues of $7.77 billion were below the Zacks Consensus Estimate of $7.79 billion. The stock has a Zacks Rank #2 (Buy).
AngioDynamics’ fiscal second-quarter adjusted EPS of 22 cents exceeded the Zacks Consensus Estimate by a penny. Revenues totaled $91.5 million, beating the consensus estimate by 2.9%. The stock carries a Zacks Rank #2. You can see the complete list of today’s Zacks #1 Rank stocks here.
CONMED delivered fourth-quarter adjusted EPS of 73 cents, in line with the Zacks Consensus Estimate. Revenues of $242.4 million beat the Zacks Consensus Estimate of $229.2 million. The stock carries a Zacks Rank of 2.
Zacks' Top 10 Stocks for 2019
In addition to the stocks discussed above, would you like to know about our 10 finest buy-and-holds for the year? Who wouldn't? Our annual Top 10s have beaten the market with amazing regularity. In 2018, while the market dropped -5.2%, the portfolio scored well into double-digits overall with individual stocks rising as high as +61.5%. And from 2012-2017, while the market boomed +126.3, Zacks' Top 10s reached an even more sensational +181.9%.
Image: Bigstock
Orthofix (OFIX) Earnings Beat Estimates in Q4, Margins Fall
Orthofix (OFIX - Free Report) reported fourth-quarter 2018 adjusted earnings of $55 cents per share, up 5.8% year over year. The figure beat the Zacks Consensus Estimate by 17%. Adjusting for the operating loss incurred due to the acquisition of Spinal Kinetics, adjusted EPS in the quarter was 62 cents, reflecting 19.2% growth over the prior-year quarter.
Reported EPS in the quarter came in at 46 cents, showing a massive year-over-year surge of 475%.
For the full year, the company delivered an adjusted EPS of $1.79, marking an increase of 10.5% from a year ago. The bottom line beat the Zacks Consensus Estimate by 2.3%.
Revenues in the fourth quarter came in at $121.1 million, up 3.6% year over year. The figure, however, missed the Zacks Consensus Estimate by 0.6%. Excluding contributions from Spinal Kinetics, net sales increased 1.4% on a reported basis and 1.7% at constant exchange rate or CER.
For the full year, revenues totaled $453 million, up 4.4% from the year-ago period. The top line missed the Zacks Consensus Estimate by a meager 0.2%.
Segmental Analysis
The key operating segment of Orthofix is Orthofix Spine which comprises product lines like Bone Growth Therapies, Spinal Implants, Biologics, Orthofix Extremities. For the quarter under review, revenues from Bone Growth Therapies totaled $52.8 million, up 6.1 % year over year both on a reported basis and at CER.
Spinal implants posted revenues of $24.9 million, up 17.9% (18.5% at CER). This included $3.59 million from spinal kinetics. Biologics recorded revenues of $16 million, down 4.8%, both on a reported basis and at CER. Revenues from Orthofix Extremities grossed $27.2 million, down 6.4% on a reported basis and 3.6% at CER.
Margin details
In the fourth quarter of 2018, gross profit increased 2.3% year over year to $95.4 million. However, gross margin contracted 100 basis points (bps) to 78.8%. Adjusted operating profit declined 28% from the year-ago quarter to $12.8 million. The decline was led by a year-over-year increase in operating expenses. As a result, operating margin contracted 472 bps to 10.6%.
Operational update
Orthofix exited 2018 with a cash equivalent of $69.6 million compared with $81.2 million at the end of 2017. Net cash from operating activities at the end of 2018 was $49.9 million, reflecting an increase from $38.9 million in the year-ago period.
Guidance for 2019
Orthofix issued the 2019 financial guidance. Adjusted EPS at the end of 2019 is projected in the band of $1.75-$1.82 million. The Zacks Consensus Estimate of $1.86 is above the high end of the guidance. Revenues at the end of 2019 are projected in the range of $472-$477 million. The Zacks Consensus Estimate of $480.5 million is also above the high end of the guidance provided by the company.
Our take
Orthofix ended 2018 on a mixed note with earnings surpassing estimates but revenues missing the same by a narrow margin. Barring Extremities and Biologics, the other key operating segments saw year-over-year revenue growth. It is concerning to note that both gross and operating margin contracted in the fourth quarter. However, the recent FDA approval of the M6-C Artificial Cervical disc reflects the steady progress in the company’s spine business.
Zacks Rank & Other Key Picks
Orthofix sports a Zacks Rank #1 (Strong Buy). A few other top-ranked medical stocks are Abbott Laboratories (ABT - Free Report) , AngioDynamics Inc. (ANGO - Free Report) and CONMED, Corp. (CNMD - Free Report) .
Abbott reported fourth-quarter 2018 adjusted EPS of 81 cents, in line with the Zacks Consensus Estimate. Revenues of $7.77 billion were below the Zacks Consensus Estimate of $7.79 billion. The stock has a Zacks Rank #2 (Buy).
AngioDynamics’ fiscal second-quarter adjusted EPS of 22 cents exceeded the Zacks Consensus Estimate by a penny. Revenues totaled $91.5 million, beating the consensus estimate by 2.9%. The stock carries a Zacks Rank #2. You can see the complete list of today’s Zacks #1 Rank stocks here.
CONMED delivered fourth-quarter adjusted EPS of 73 cents, in line with the Zacks Consensus Estimate. Revenues of $242.4 million beat the Zacks Consensus Estimate of $229.2 million. The stock carries a Zacks Rank of 2.
Zacks' Top 10 Stocks for 2019
In addition to the stocks discussed above, would you like to know about our 10 finest buy-and-holds for the year? Who wouldn't? Our annual Top 10s have beaten the market with amazing regularity. In 2018, while the market dropped -5.2%, the portfolio scored well into double-digits overall with individual stocks rising as high as +61.5%. And from 2012-2017, while the market boomed +126.3, Zacks' Top 10s reached an even more sensational +181.9%.
See Latest Stocks Today >>